We will explore the influence of urinary acidification by l-Methionine on bone metabolism and acid base status in order to evaluate whether this treatment could be a potential risk factor for osteoporosis or not. At present this long term therapy to avoid recurrent urinary tract infection and struvite stones is regarded as a treatment without any negativ impact on bone metabolism. MedDRA version: 9.1 Level: LLT Classification code 10031282 Term: Osteoporosis
Conditions
Interventions
Trade Name: Acimethin
Pharmaceutical Form: Film-coated tablet
CAS Number: 63683
Other descriptive name: L-METHIONINE
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number:
Sponsors
Medizinische Universität Graz
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: - healthy male individuals - age between 20 and 40 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: - Homocysteinuria - Hyperuricemia - Cystin stones - Renal insufficiency - Hepatic insufficiency - Hyperoxaluria - Methionine adenosyltransferase deficiency - Metabolic acidosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The impact of l-methionine intake on bone metabolism. ;Secondary Objective: ;Primary end point(s): - Osteocalcin (Plasma) - Crosslaps (Plasma) | — |
Countries
Austria
Outcome results
None listed